This trial is enrolling individuals with acute cervical (neck area) spinal cord injuries to assess an experimental drug (NG-101). In earlier studies, NG-101 appeared to neutralize a molecule in the spinal cord that blocks nerve growth. The research team wants to see if the drug promotes nerve regeneration. If selected for the study, participants must begin the series of drug injections within 4 to 28 days following SCI. Each will be randomly assigned to one of two study groups: 1) receiving six injections of NG-101 over 30 days, or 2) receiving six injections of a placebo over 30 days. This study hopes to build on evidence from a smaller preliminary trial that demonstrated reasonable safety and tolerability of this drug.
Traumatic
Type
Details
- The participant will be randomly assigned to one of the two study groups: 1) Those receiving six injections of NG-101 over 30 days, or 2) those receiving six injections of a placebo over 30 days. - Over a period of 24 weeks: physical examinations, functional activity testing, testing of how nerves are functioning using nerve stimulation techniques, and measurements of drug concentrations in the spinal fluid obtained by spinal tap
Main benefits
Arm/hand function
Additional benefits
Bladder health/function
General health
Mental health and psychosocial factors
Standing/walking/mobility
Good to know: Potential benefits are defined as outcomes that are being measured during and/or after the trial.
Wings for Life has proudly initiated, led and funded the new version of the SCI Trials Finder website. Wings for Life aims to find a cure for spinal cord injuries. The not-for-profit foundation funds world-class scientific research and clinical trials around the globe.
Learn moreWings for Life has proudly initiated, led and funded the new version of the SCI Trials Finder website. Wings for Life aims to find a cure for spinal cord injuries. The not-for-profit foundation funds world-class scientific research and clinical trials around the globe.
Learn more